Scienture Holdings, Inc.

SCNX

US80880X1046

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 02:04:28 30/06/26 am AEST			5-day change	1st Jan Change
0.3550 ^USD	-1.44%		-7.15%	-30.47%

19/06	Scienture Holdings Expands Arbli Payor Coverage and Commercial Access	CI
09/06	Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team	CI

Top Midday Decliners

Published on 08/15/2025 at 03:56 am AEST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Scienture Holdings, Inc.

19/06	Scienture Holdings Expands Arbli Payor Coverage and Commercial Access	CI
09/06	Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team	CI
02/06	Scienture Secures US Patent Protection for Rezenopy Through 2041	MT
30/05	Scienture - Eric Sherb resigns as CFO effective May 26, 2026	RE
30/05	Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026	CI
16/05	Scienture Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	Scienture secures $11.0 million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of research and development pipeline	RE
07/05	Scienture Holdings, Inc. Secures $11 Million in Non-Dilutive Debt Financing	CI
27/04	Scienture Holdings, Inc. announced that it has received $11 million in funding	CI
31/03	Scienture reports year end 2025 financial results and provides business update	RE
30/03	Scienture Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/03	Scienture Holdings, Inc. Auditor Raises 'Going Concern' Doubt	CI
12/03	Scienture Broadens Commercial Access for Rezenopy, Highest-Dose Fda-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching over 5,000 U.S. Institutions	CI
04/02	Scienture provides commercial update on Arbli(TM), the first FDA-approved ready-to-use oral suspension of losartan potassium	RE
04/02	Scienture Provides Commercial Update on ARBLI , the First FDA-Approved Ready-To-Use Oral Suspension of Losartan Potassium	CI

Chart Scienture Holdings, Inc.

Duration

Period

SCNX: Dynamic Chart

Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Employees

Sector

Pharmaceuticals

More about the company